Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 2.27% is 69% below its 5-year average of 7.40%, near the low end of its 5-year range (0.89%–958.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 42.08% below its 12-month average of 3.92%.
Reported quarterly debt to assets ratio; no daily interpolation. Q1 FY2027 (2026-06-30): 2.27%.
DEBT TO ASSETS RATIO
2.27%
DEBT TO ASSETS RATIO AVG TTM
3.92%
DEBT TO ASSETS RATIO AVG 3Y
7.21%
DEBT TO ASSETS RATIO AVG 5Y
7.40%
DEBT TO ASSETS RATIO AVG 10Y
5.29%
DEBT TO ASSETS RATIO AVG 15Y
6.29%
DEBT TO ASSETS RATIO AVG 20Y
6.29%
CURRENT VS TTM AVG
-42.08%
CURRENT VS 3Y AVG
-68.54%
CURRENT VS 5Y AVG
-69.36%
CURRENT VS 10Y AVG
-57.12%
CURRENT VS 15Y AVG
-63.91%
CURRENT VS 20Y AVG
-63.91%
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 732 covered companies
CURRENT VS SECTOR MEDIAN
+2168.83%
vs the sector median at left
Modular Medical, Inc.
Market Cap
$21.03M
Debt to Assets Ratio
2.27%
TTM Avg
3.92%
3Y Avg
7.21%
5Y Avg
7.40%
Market Cap
$20.67M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$20.09M
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$19.66M
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$22.65M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$22.78M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$18.54M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Modular Medical, Inc. (MODD) | $21.03M | 2.27% | 3.92% | 7.21% | 7.40% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.67M | 0.07% | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $20.09M | 0.08% | N/A | N/A | N/A |
| P3 Health Partners Inc. (PIII)vs › | $19.66M | 0.20% | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.44M | 0.01% | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.65M | 0.17% | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $22.78M | 0.00% | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $19.06M | 0.19% | N/A | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.54M | 0.00% | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.40M | 0.00% | N/A | N/A | N/A |
Debt/Assets
2.3%
Debt/Equity
0.03
Current Ratio
3.25
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 2.27% |
| 2026-03-31 | 2.65% |
| 2025-12-31 | 4.91% |
| 2025-09-30 | 4.71% |
| 2025-06-30 | 5.05% |
| 2025-03-31 | 4.36% |
| 2024-12-31 | 7.52% |
| 2024-09-30 | 11.50% |
| 2024-06-30 | 10.92% |
| 2024-03-31 | 8.62% |
| 2023-12-31 | 20.60% |
| 2023-09-30 | 13.51% |
| 2023-06-30 | 10.53% |
| 2023-03-31 | 21.33% |
| 2022-12-31 | 0.89% |
| 2022-09-30 | 1.00% |
| 2022-06-30 | 1.04% |
| 2022-03-31 | 1.88% |
| 2021-12-31 | 958.00% |
| 2021-09-30 | 371.25% |
| 2021-06-30 | 115.01% |
| 2021-03-31 | 125.08% |
| 2020-12-31 | 60.15% |
| 2020-09-30 | 38.16% |
| 2020-06-30 | 23.58% |
| 2020-03-31 | 7.02% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.01% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 5.42% |
| 2015-09-30 | 19392.64% |
| 2015-06-30 | 4817.16% |
| 2015-03-31 | 2712.85% |
| 2014-12-31 | 1863.12% |
| 2005-03-31 | 0.00% |
| 2004-12-31 | 0.00% |
| 2004-09-30 | 0.00% |
